AnaptysBio, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +107.7%
EBITDA: +176.6%
EBIT: +140.7%
EPS: +82.7%
Free cash flow: +104.0%
Operating cash flow: +104.1%

Forward estimates

Revenue: -58.3%
EBITDA: —
EPS: —

Three-year CAGR

Revenue: +183.6%
EBITDA: +174.7%
EBIT: +141.7%
Net income: +90.9%
EPS: +91.0%
Free cash flow: +114.5%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.